MBX — MBX Biosciences Balance Sheet
0.000.00%
- $306.50m
- $44.35m
Annual balance sheet for MBX Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 42.5 | 80.7 | 262 |
Net Total Receivables | 0.142 | 0.208 | 0.682 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 44.2 | 83.5 | 267 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 0.842 | 0.665 | 1.2 |
Other Long Term Assets | |||
Total Assets | 45.1 | 84.2 | 269 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Current Liabilities | 3.43 | 3.93 | 11.1 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 3.82 | 4.29 | 11.1 |
Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Other Equity | |||
Total Equity | 41.3 | 79.9 | 257 |
Total Liabilities & Shareholders' Equity | 45.1 | 84.2 | 269 |
Total Common Shares Outstanding |